NewCardio receives European patent for wireless ECG technology

19 March 2008

NewCardio, Inc. (OTCBB: NWCI), a development-stage cardiac diagnostic and services company, announced today that it has received a Certificate of Grant from the European Patent Office covering CardioBip, its proprietary device and methodology for transtelephonic transmission of comprehensive ECG data.

The CardioBip is a hand-held device that can wirelessly transmit 12-lead ECG data and offers the potential for integration with popular hand-held PDA platforms.

The patent award adds to the company's IP portfolio, which includes US Patents awarded in 2007 for technology underlying its VisualECG and QTinno products, and several US and international patent applications currently under review. The patent application, with 33 claims covering the device, is also being reviewed in the US, China, Japan, and Korea.

Dr Branislav Vajdic, chief executive officer of NewCardio, Inc., commented, “We believe the CardioBip technology has an important role to play in detection and monitoring of potentially fatal cardiac diseases. Thus, we are gratified by the European Patent Office’s broad grant of patent rights. We look forward to hearing soon from other patent offices, including the US Patent and Trademark Office. NewCardio is committed to advancing the widely accepted 12-lead ECG to deliver innovation to the cardiac sciences.”

To top